Singapore markets closed

Prothena Corporation plc (PRTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
27.59-1.39 (-4.80%)
At close: 04:00PM EST
27.74 +0.15 (+0.54%)
After hours: 08:00PM EST

Prothena Corporation plc

77 Sir John Rogerson’s Quay
Block C Grand Canal Docklands
Dublin D02 VK60
Ireland
353 1 236 2500
https://www.prothena.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees173

Key executives

NameTitlePayExercisedYear born
Dr. Gene G. Kinney Ph.D.President, CEO & Director1.03M2.91M1969
Mr. Tran B. Nguyen M.B.A.CFO & Chief Strategy Officer762.86k3.84M1974
Mr. Brandon S. SmithChief Operating Officer756.41kN/A1975
Ms. Carol D. KarpChief Regulatory Officer697.51kN/A1953
Dr. Hideki Garren M.D., Ph.D.Chief Medical Officer809.59k526.1k1965
Ms. Karin L. Walker CPAChief Accounting Officer & ControllerN/AN/A1963
Dr. Wagner M. ZagoChief Scientific Officer478.79kN/A1973
Mr. Mark C. Johnson C.F.A.Vice President of Investor RelationsN/AN/AN/A
Mr. Michael J. MalecekChief Legal Officer & Company Secretary588.25kN/A1966
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Corporate governance

Prothena Corporation plc’s ISS governance QualityScore as of 28 February 2024 is 4. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.